These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15577944)

  • 41. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of the degradation function of Mdm2.
    Kubbutat MH; Ludwig RL; Levine AJ; Vousden KH
    Cell Growth Differ; 1999 Feb; 10(2):87-92. PubMed ID: 10074902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gankyrin: a new oncoprotein and regulator of pRb and p53.
    Dawson S; Higashitsuji H; Wilkinson AJ; Fujita J; Mayer RJ
    Trends Cell Biol; 2006 May; 16(5):229-33. PubMed ID: 16581249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2.
    Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W
    Science; 2003 Dec; 302(5652):1972-5. PubMed ID: 14671306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The levels of MDM2 protein are decreased by a proteasome-mediated proteolysis prior to caspase-3-dependent pRb and PARP cleavages.
    Cho JW; Park JC; Lee JC; Kwon TK; Park JW; Baek WK; Suh SI; Suh MH
    J Korean Med Sci; 2001 Apr; 16(2):135-9. PubMed ID: 11306736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulation of p53 degradation via MDM2-mediated ubiquitylation and the ubiquitin-proteasome system during reperfusion after stroke: role of oxidative stress.
    Saito A; Hayashi T; Okuno S; Nishi T; Chan PH
    J Cereb Blood Flow Metab; 2005 Feb; 25(2):267-80. PubMed ID: 15678128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.
    Li L; Liao J; Ruland J; Mak TW; Cohen SN
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1619-24. PubMed ID: 11172000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modification of MDMX by sumoylation.
    Pan Y; Chen J
    Biochem Biophys Res Commun; 2005 Jul; 332(3):702-9. PubMed ID: 15907800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
    Wunderlich M; Berberich SJ
    Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
    Argentini M; Barboule N; Wasylyk B
    Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.
    Yin Y; Stephen CW; Luciani MG; Fåhraeus R
    Nat Cell Biol; 2002 Jun; 4(6):462-7. PubMed ID: 12032546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mdm2 promotes the rapid degradation of p53.
    Haupt Y; Maya R; Kazaz A; Oren M
    Nature; 1997 May; 387(6630):296-9. PubMed ID: 9153395
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
    Swaroop M; Sun Y
    Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 56. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2.
    Xirodimas DP; Chisholm J; Desterro JM; Lane DP; Hay RT
    FEBS Lett; 2002 Sep; 528(1-3):207-11. PubMed ID: 12297306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein.
    Sdek P; Ying H; Chang DL; Qiu W; Zheng H; Touitou R; Allday MJ; Xiao ZX
    Mol Cell; 2005 Dec; 20(5):699-708. PubMed ID: 16337594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Significance of MDM2 protein in the cell cycle].
    Szemraj J; Rozpończyk E; Bartkowiak J; Greger J; Oszajca K
    Postepy Biochem; 2005; 51(1):44-51. PubMed ID: 16209341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regulation of MyoD activity and muscle cell differentiation by MDM2, pRb, and Sp1.
    Guo CS; Degnin C; Fiddler TA; Stauffer D; Thayer MJ
    J Biol Chem; 2003 Jun; 278(25):22615-22. PubMed ID: 12702724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2.
    Maki CG
    J Biol Chem; 1999 Jun; 274(23):16531-5. PubMed ID: 10347217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.